PDGFR expression has been demonstrated in a number of solid tumors including ACC.[70, 71] These results suggested that imatinib, a small molecule inhibitor of the c-ABL, PDGFR and stem cell ligand receptor (c-KIT) tyrosine kinases, could potentially have activity in ACC. This evidence concerns the gene KIT and adrenal cortex carcinoma.